Research groups

GC08 Hormones and Cancer

The Hormones and Cancer research group is a consolidated group of the IMIBIC comprised by basic, translational, and clinical researchers. We investigate the cellular and molecular principles underlying the natural processes of neuroendocrine-metabolic regulation and their dysfunctions in tumors and cancer. The group pays special attention to the role played by certain neuropeptide/receptor systems and their regulation by distinct mechanisms, especially alternative splicing and its related RNA controlling processes and associated signalling pathways, at the onco-endocrine interface. The original focus of our group laid on the study of pituitary cell biology, particularly growth hormone (GH)-producing somatotropes and their regulatory signals (somatostatin, cortistatin, GHRH, ghrelin, Kisspeptins, etc.) and receptors (SST1-5, GHRHR, GHSR1, KISS1R), and signalling pathways. This line evolved to study pituitary neuroendocrine tumors (PitNETs) and expanded definitely with the discovery of novel, abnormal splicing variants (SST5TMD4, In1-ghrelin) and the study of their pathophysiological role in somatotropes and other endocrine cell types (eg. corticotropes, gonadotropes, pancreatic beta cells) and, broadly, in tumor development and metabolic dysfunction. Currently, our work is centred in the pathophysiology of neuroendocrine tumors (NETs) from pancreatic, gastrointestinal and lung origin, and of pancreatic ductal adenocarcinoma (PDAC), wherein we investigate the actions of diverse molecular regulatory systems (including somatostatin, ghrelin, etc.) and the specific role of alternative splicing and RNA biology.

To achieve our goals, we use a wide range of techniques, including primary cultures of normal and tumor cells, cell lines, genetically modified animals, measurements of peptides, hormones, second messengers and gene expression of diverse molecular components, particularly of the spliceosome machinery, as well as dynamic imaging of molecular trafficking, confocal microscopy in living cells, etc. We are developing and applying biocomputational approaches to explore the spliceosomic landscape in different experimental and clinical settings with the aim of further understanding the contribution of splicing and RNA metabolism to cancer and other diseases.

Our studies have led to the discovery and characterization of new receptors, splicing variants, functions and mechanisms of action for different neuroendocrine-metabolic signals and drugs controlling hormone secretion, tumorigenesis or cell death and survival in normal and pathological conditions, such as metabolic dysregulations (diabetes, obesity) and cancer (PitNETs, NETs, pancreatic cancer, and breast, prostate, and liver cancers, among others). Our ultimate aim is to contribute to the discovery of novel biomarkers for early detection, improved diagnosis and predictive prognosis of the tumors studied, as well as to identify actionable targets for the design of innovative personalized therapeutic strategies, which would jointly enable the advancement of precision medicine in NETs and pancreatic cancer.

Research Lines

Networks

    CIBERobn Physiopathology of Obesity and Nutrition

    GETNE - Spanish Group of Neuroendocrine Tumours – Spanish Society of Medical Oncology

    TransBioNet – Spanish Bioinformatics Network for Clinical Research

    Area of Knowledge of Neuroendocrinology – Spanish Society of Endocrinology and Nutrition

    Neuroendocrinology Work Group – Andalusian Society of Endocrinology, Diabetes and Nutrition

    REMAH - Spanish Molecular Registry of Hypophyseal Adenomas

    PAIDI BIO-139 Cellular and molecular endocrinology (Andalusian Plan for Research, Development and Innovation - PAIDI)

    ceiA3 - Agrifood Campus of International Excellence

Keywords

  • Cellular and molecular endocrine oncology
  • pancreatic cancer
  • neuroendocrine tumors
  • pituitary tumors
  • alternative splicing
  • splice-variants
  • spliceosome
  • somatostatin
  • somatostatin-receptors
  • cortistatin
  • ghrelin
  • signaling

Additional Information

5 most relevant publicactions (2017-2019)

1- Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortés E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remón P, Solivera J, Wildemberg LE, Kasuki L, López-Fernandez JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP*, Luque R; Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features. CANCERS.11.10.1439. DOI: 10.3390/cancers11101439. IF: 6,162. (D2 Q1; Oncology) *Co-senior author

2- Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler MD, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacol Rev 2018, 70(4):763-835. IF: 18.886. (D1; Pharmacology & pharmacy)

3- Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP*, Luque RM. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. Mol Cancer 2017, 16(1):146. IF: 10.679 (D1; Oncology) *Co-senior author

4- Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Salas RO, Serrano-Blanch R, Salvatierra Á, Hofland LJ, Luque RM, Gálvez-Moreno MA, Castaño JP. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. Lung Cancer 2017, 109:128-136. FI: 4.599. (Q1; Respiratory System)

5- Gahete MD, Del Rio-Moreno M, Camargo A, Alcalá-Diaz JF, Alors-Pérez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martínez P, Castaño JP*, Lopez-Miranda J, Luque RM. Changes in splicing machinery components influence, precede, and early predict the development of type 2 diabetes: From the CORDIOPREV study. EBioMedicine 2018, 3964(18)30479-1. IF: 6.183. (D1; Medicine, Research & Experimental area) *Co-senior author

Ongoing projects

1. Alterations in the alternative splicing machinery in pancreatic cancer: Identifications of novel diagnostic, prognostic and therapeutic biomarkers. BFU2016-80360-R.  PI: Justo P Castaño. Ministerio de Economía y Competitividad (MINECO). 2017-2019. 181.500€

2. Spliceosomic strategy to improve the diagnostic, classification and treatment of pancreatic neuroendocrine tumors. G1909. PI: Justo P Castaño. Beca GETNE 2019. 2020-2022. 60.000 €

3. IMIBIC Fellowship Programme for Personalised and Precision Medicine (P2Med): H2020 MSCA COFUND FP 2018. GA nr: 847468. Coordinator: Justo P Castaño. (IMIBIC). 2019-2024. EC Funding: 662.040 €. (Total cost 1.183.680 €).

4. Promoting STEM vocations from Biomedicine. FCT-18-13958. PI: Justo P Castaño. FECYT. 2019-2020. 20.000€.

5. Spliceosomic strategy in NETs for the improvement of diagnostic, classification and treatment. FERP2019. PI: Justo P Castaño. Fundación Eugenio Rodríguez Pascual 2019. 2019-2020. 7.000 €

6. Analysis of the in vitro combination of trastuzumab and lirilumab in breast cancer. Involvement of alternative splicing processes. PI: Cristina Morales Estévez. Sociedad Española de Oncología Médica (Beca FSEOM/BMS - Proyectos de investigación traslacional en Inmuno-Oncología 2018). 2019-2020. 40.000€.

7. Diagnosis and personalized postoperative prognosis of human gliomas using a new interactive approach. PI-0143-2016. PI: Juan Solivera Vela. Consejería de Salud (Junta de Andalucía). 2017-2019. 46.970,42 €

8. Molecular and functional characterization of bladder cancer: search of novel therapies. PI: Raúl M Luque. Eli Lilly & Company. 46.200 €. 2019-20.

9. Ghrelin-O-acyl-Transferase (GOAT): New Biomarker for the screening of prostate cancer. DTS18/00131. PI: Raúl M Luque. Instituto de Salud Carlos III. Proyectos de Desarrollo Tecnológico en Salud. 2018-2020. 88.550€.

10. Ghrelin-O-aciltransferase (GOAT):  new biomarker for prostate cancer. (FIPSE Project 3188-17). PI: Raúl M Luque. 2018-2019. 30.000€.

PATENTS

1. Isoforms of the human somatostatin receptor type 5 produced by alternative processing and pairs of oligonucleotides for detection by PCR. Castaño JP, Durán Prado M, Martínez Fuentes AJ, Vázquez-Martínez R, García Navarro S, Gracia-Navarro F, Malagón MM. P200502701.

2. Ghrelin variant and its use. Luque RM, Castaño JP, Gahete MD, Gracia-Navarro F, Martínez-Fuentes AJ, Córdoba-Chacón J, Benito P, Kineman RD. P201030905.

3. Ghrelin-O-acyltransferase (GOAT) and its use. Castaño JP, Luque RM, Gahete MD, Hormaechea-Agulla D, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J, Ibáñez-Costa A, Moreno MM, Valero-Rosa J. P201531731 - PCT/ES2016/070844

4. Non-invasive diagnostic method for cancer. Castaño JP, Luque RM, Gahete MD, Ibáñez-Costa A, Hormaechea-Agulla D, Jiménez-Vacas JM, Sarmento-Cabral A, L-López F, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J.P201631606 - PCT/ES2017/070797

5. Peptides derived from the truncated somatostatin receptor sst5TMD4 as biomarkers and therapeutic targets in tumor pathologies. Luque RM, Castaño JP, Gahete MD, del Río-Moreno M, Alors-Pérez E. P201730702 - PCT/ES2018/070361

6. Method for the prediction and prognostic of the development of type 2 diabetes mellitus. Castaño JP, Luque RM, Gahete MD, López-Miranda J, Pérez-Martínez P, Delgado-Lista J, García-Ríos A, Alcalá-Díaz JF, Yubero-Serrano E, Camargo-García A, del Río-Moreno M, Alors-Pérez E, Ventura-Soto S, Reyes-Pupo O. P201831095

7. Method for the diagnosis, prognosis and treatment of neuroendocrine tumors. Castaño JP, Luque RM, Gahete MD, Pedraza-Arévalo S, del Río-Moreno M, Alors-Pérez E, Gálvez-Moreno MA, Herrera-Martínez A, Serrano-Blanch R. P201831039

8. Method for the diagnosis and prognosis of the development of prostate cancer. Castaño JP, Luque RM, Gahete MD, Jiménez-Vacas JM, Sarmento-Cabral A, L-López F, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J. P201930104

9. Method of obtaining useful data for the diagnosis, stratification and / or follow-up of patients with rheumatoid arthritis. Castaño JP, Luque RM, López-Pedrera R, Pérez-Sánchez C, Collantes-Estévez E, Ortega-Castro R, Ibáñez-Costa A, Pedraza-Arévalo S, del Río-Moreno M, Barbarroja-Puerto N, Jimenez-Gomez Y. P201930123

10. Method for the diagnosis and prognosis of the development of brain tumors. Luque RM, Gahete MD, Fuentes-Fayos AC, Castaño JP, Ibáñez-Costa A, Vázquez-Borrego MC, López-López F, Blanco-Acebedo C, Solivera-Vela J, Toledano-Delgado A, Gálvez-Moreno MA. P201931147.

GC08 Hormones and Cancer

Principal Investigator
Justo P. Castaño Fuentes

Researchers
Francisco Gracia Navarro
Cristóbal José Blanco Acevedo
Sergio Pedraza Arévalo

Pre-Doctoral Researchers
Ricardo Blázquez Encinas-Rey
Mª Teresa Caro Cuenca
Antonio Carlos Fuentes Fayos
Manuel Jiménez Fuyer
Paloma Moreno Moreno
Marina Esther Sánchez Frías
Javier del Teso Rodríguez

Technical Staff
Esther Rivero Cortés

Projects

Active Projects

National

Castaño JP. Spliceosomic strategy to improve the diagnostic, classification and treatment of pancreatic neuroendocrine tumors. Funding agency: Spanish Group for the Study of Neuroendocrine Tumors - GETNE 2019. Reference: G1909.

Castaño JP. Promoting STEM vocations from Biomedicine. Funding agency: Spanish Foundatiotion for Science and Technology-FECYT. Reference: FCT-18-13958.

Castaño JP. Spliceosomic strategy in NETs for the improvement of diagnostic, classification and treatment. Funding agency: Fundación Eugenio Rodríguez Pascual. Reference: G1909.

Morales-Estévez C (IP). Analysis of the in vitro combination of trastuzumab and lirilumab in breast cancer. Involvement of alternative splicing processes. Funding agency: Sociedad Española de Oncología Médica (Beca FSEOM/BMS - Reference: Proyectos de investigación traslacional en Inmuno-Oncología 2018

Valencia A (IP); Córdoba Node: Castaño JP. Consolidating the traslational bioinformatic Network TransBioNet (Research Networks). Spanish Ministry for Science, Innovation and Universities. RED2018-102404-T.

Gahete MD (IP). Identification of new diagnostic, prognostic and/or therapeutic targets associated with the dysregulation of splicing mechanisms in neuroendocrine pituitary tumors. Fundación de la Sociedad Española de Endocrinología y Nutrición (FSEEN).

International

IMIBIC Fellowship Programme for Personalised and Precision Medicine (P2Med): H2020 MSCA COFUND FP 2018. GA nr: 847468. Coordinator: Justo P Castaño. 2019-2024. EC Funding: 662.040 €. (Total cost 1.183.680 €) (IMIBIC). 2019-2024.

Publications

Main Publications 2019

Herrera-Martínez AD, Pedraza-Arévalo S, L-López F, Gahete MD, Gálvez-Moreno MA, Castaño JP*, Luque RM. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution? JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2019. 104. 1. 57-73. DOI:10.1210/jc.2018-01455.
IF: 5,605
Q:1

Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortés E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remon P, Solivera J, Wildemberg LE, Kasuki L, López-Fernandez JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP*, Luque R. Splicing machinery is dysregulated in pituitary neuroendocrine tumors and is associated with aggressiveness features. CANCERS. 2019. 11.10.1439. DOI: 10.3390/cancers11101439.  *Co-senior author
IF: 6,162
Q:1 D: 2

Del Río-Moreno M, Alors-Pérez E, De Souza PB, Prados-González ME, Castaño JP*, Luque RM, Gahete MD; Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. 2019. TRANSLATIONAL RESEARCH. 211. (147-160). DOI: 10.1016/j.trsl.2019.02.013. *Co-senior author
IF: 4,915
D: 1

Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Moreno MAG, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted systemic treatment of neuroendocrine tumors: Current options and future perspectives. 2019. DRUGS. 79. 1. 21-42. DOI: 10.1007/s40265-018-1033-0.
IF: 4,993
Q: 1

Herrera-Martínez AD, Hofland LJ, Moreno MAG, Castaño JP, de Herder WW, Feelders RA. Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. 2019. ENDOCRINE-RELATED CANCER. 26. 3. R157-R179. DOI:10.1530/ERC-18-0354.
IF: 4,774
Q: 1

Other Publications 2019

Jiménez-Vacas JM, Herrero-Aguayo V, Gómez-Gómez E, León-Gonzalez AJ, Saez-Martínez P, Alors-Pérez E, Fuentes-Fayos AC, Martínez-López A, Sánchez-Sánchez R, González-Serrano T, López-Ruiz DJ, Requena-Tapia MJ, Castaño JP, Gahete MD Luque RM; Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. 2019. TRANSLATIONAL RESEARCH. 212. (89-103). DOI: 10.1016/j.trsl.2019.07.001.
IF: 4,915.
D1

Gómez-Gómez, E; Jiménez-Vacas, JM; Pedraza-Arévalo, S; López-Lopez, F; Herrero-Aguayo, V; Hormaechea-Agulla, D; Valero-Rosa, J; Ibáñez-Costa, A; León-González, AJ; Sánchez-Sánchez, R; Gonzalez-Serrano, T; Requena-Tapia, MJ; Castaño, JP, Carrasco-Valiente, Luque RM. Oncogenic role of secreted engrailed homeobox 2 (EN2) in prostate cancer. 2019. JOURNAL OF CLINICAL MEDICINE.8.9.1400. DOI: 10.3390/jcm8091400.
IF: 5,688.
D1

Biagetti B, Herance JR, Ferrer R, Aulinas A, Palomino-Schatzlein M, Mesa J, Castaño JP, Luque RM, Simó R; Metabolic fingerprint of acromegaly and its potential usefulness in clinical practice. 2019. JOURNAL OF CLINICAL MEDICINE. 8.10.1549. DOI: 10.3390/jcm8101549.
IF: 5,688.
D1

Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. 2019. BRITISH JOURNAL OF PHARMACOLOGY. 176 Suppl 1:S21-S141. doi: 10.1111/bph.14748.
IF: 6.583.
D1

Fernández-Bedmar Z, Anter J, Alonso-Moraga A, Delgado de la Torre P, Luque de Castro MD, Millán-Ruiz Y, Sánchez-Frías M, Guil-Luna S. Red and white wine lees show inhibitory effects on liver carcinogenesis. 2019. MOLECULAR NUTRITION FOOD RESEARCH. 2019 63(9):e1800864
IF: 4.653.
D1

Jiménez-Vacas JM, Gómez-Gómez E, Montero-Hidalgo AJ, Herrero-Aguayo V, L-López F, Sánchez-Sánchez R, Guler I, Blanca A, Méndez-Vidal MJ, Carrasco J, Lopez-Miranda J, Requena-Tapia MJ, Castaño JP, Gahete MD, Luque RM. Clinical utility of ghrelin-o-acyltransferase (GOAT) enzyme as a diagnostic tool and potential therapeutic target in prostate cancer. 2019. JOURNAL OF CLINICAL MEDICINE.  22. 8. (12). DOI: 10.3390/jcm8122056.
IF: 5,583.
D1

Vázquez-Borrego MC, Fuentes-Fayos AC, Herrera-Martínez AD, L-López F, Ibáñez-Costa A, Moreno-Moreno P, Alhambra-Expósito MR, Barrera-Martin A, Blanco-Acevedo C, Dios E, Venegas-Moreno E, Solivera J, Gahete MD, Soto-Moreno A, Galvez-Moreno MA, Castaño JP, Luque RM; Biguanides exert antitumoral actions in pituitary tumor cells through AMPK-dependent and -independent mechanisms. 2019. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3501-3513). DOI: 10.1210/jc.2019-00056.
IF: 5,605.
Q1

del Río-Moreno M, Alors-Pérez E, González-Rubio S, Ferrín G, Reyes O, Rodríguez-Peralvarez M, Saáchez-Frías ME, Sánchez-Sánchez R, Ventura S, López-Miranda J, Kineman RD, de la Mata M, Castaño JP, Gahete MD, Luque RM; Dysregulation of the splicing machinery is associated to the development of nonalcoholic fatty liver disease.2019.  JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 104. 8. (3389-3402). DOI: 10.1210/jc.2019-00021.
IF: 5,605.
Q1

Venegas-Moreno E, Flores-Martínez A, Dios E, Vázquez-Borrego MC, Ibáñez-Costa A, Madrazo-Atutxa A, Japón MA, Castaño JP, Luque RM, Cano DA, Soto-Moreno A. E-cadherin expression is associated with somatostatin analogue response in acromegaly. 2019. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 23. 5. (3088-3096). DOI: 10.1111/jcmm.13851.
IF: 4,658.
Q1

Gahete MD, Jiménez-Vacas JM, Alors-P´rrez E, Herrero-Aguayo V, Fuentes-Fayos AC, Pedraza-Arévalo S, Castaño JP, Luque RM. Mouse models of endocrine tumors. 2019. JOURNAL OF ENDOCRINOLOGY. 240. 3. (R73-R96). DOI: 10.1530/JOE-18-0571.
IF: 4,381.
Q1

Guerrero M, Ferrín G, Rodríguez-Perálvarez M, González-Rubio S, Sánchez-Frías M, Amado V, Pozo JC, Poyato A, Ciria R, Ayllón MD, Barrera P, Montero JL, de la Mata M. mTOR expression in liver transplant candidates with hepatocellular carcinoma: impact on histological features and tumour recurrence. 2019. Int J Mol Sci. 20(2). pii: E336
IF: 4.172.
Q2

Herrera-Martínez AD, Feelders RA, de Herder WW, Castaño JP, Moreno MAG, Dogan F, van Dungen R, van Koetsveld P, Hofland LJ. Effects of ketoconazole on ACTH-producing and non-ACTH-producing neuroendocrine tumor cells. 2019. HORMONES & CANCER. 10. 43526. 107-119. DOI:10.1007/s12672-019-00361-6.
IF: 2,581.
Q3

Fuentes-Fayos AC, García-Martínez A, Herrera-Martínez AD, Jiménez-Vacas JM, Vázquez-Borrego MC, Castaño JP, Pico A, Gahete MD, Luque RM; Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors. 2019. MINERVA ENDOCRINOLOGICA. 44. 2. (109-128). DOI: 10.23736/S0391-1977.19.02970-5.
IF: 1,817.
Q4

Main Publications 2018

Gunther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp HJ, Lupp A, Korbonits M, Castaño JP, Wester HJ, Culler M, Melmed S, Schulz S. International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacological Rev 2018, 70(4):763-835. IF: 18.886 (Decil 1; Pharmacology & pharmacy area)

Herrera-Martínez AD, Gahete MD, Sánchez-Sánchez R, Alors-Pérez E, Pedraza-Arévalo S, Serrano-Blanch R, Martínez-Fuentes AJ, Gálvez-Moreno MA, Castaño JP, Luque RM. Ghrelin-O-Acyltransferase (GOAT) enzyme as a novel potential biomarker in gastroenteropancreatic neuroendocrine tumors. Clin Transl Gastroenterol 2018, 9(10):196. FI: 4.803. (Quartile 1; Medicine, Research& Experimental area)

Pedraza-Arévalo S, Gahete MD, Alors-Perez E, Luque RM, Castaño JP. Multilayered heterogeneity as an intrinsic hallmark of neuroendocrine tumors. Rev Endocr Metab Disord 2018, 19(2)179-192. IF: 5. 516. (Quartile 1; Endocrinology and Metabolism area)

Alhambra-Expósito MR, Ibáñez-Costa A, Moreno-Moreno P, Rivero-Cortés E, Vázquez-Borrego MC, Blanco-Acevedo C, Toledano-Delgado Á, Lombardo-Galera MS, Vallejo-Casas JA, Gahete MD, Castaño JP, Gálvez MA, Luque RM. Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas. Sci Rep 2018, 8(1):6173. FI: 4.011. (Quartile 1; Multidisciplinary Sciences area)

Gahete MD, Del Rio-Moreno M, Camargo A, Alcala-Diaz JF, Alors-Perez E, Delgado-Lista J, Reyes O, Ventura S, Perez-Martínez P, Castaño JP, Lopez-Miranda J, Luque RM. Changes in splicing machinery components influence, precede, and early predict the development of type 2 diabetes: From the CORDIOPREV study. EBioMedicine 2018, 3964(18)30479-1. IF: 6.680. (Decil 1; Medicine, Research & Experimental area)

Other Publications 2018

Herrera-Martínez AD, Gahete MD, Pedraza-Arévalo S, Sánchez-Sánchez R, Ortega-Salas R, Serrano-Blanch R, Luque RM, Gálvez-Moreno MA, Castaño JP. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors. Endocrine 2018, 59(2):426-437. IF: 3.296. (Quartile 2; Endocrinology & Metabolism area)

Vázquez-Borrego MC, Fuentes-Fayos AC, Gahete MD, Castaño JP, Kineman RD, Luque RM. The pituitary gland is a novel major site of action of metformin in non-human primates: A potential path to expand and integrate its metabolic actions. Cell Physiol Biochem 2018, 49(4):1444-1459. IF: 5.500. (Decil 1; Physiology area)

Vázquez-Borrego MC, Gahete MD, Martínez-Fuentes AJ, Fuentes-Fayos AC, Castaño JP, Kineman RD, Luque RM. Review. Multiple signaling pathways convey central and peripheral signals to regulate pituitary function: lessons from human and non-human primate models. Mol Cell Endocrinol 2018, 463:4-22. IF: 3.693 (Quartile 2; Endocrinology & Metabolism area)     

Rincón-Fernández D, Culler MD, Tsomaia N, Moreno-Bueno G, Luque RM, Gahete MD, Castaño JP. In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines. Carcinogenesis 2018, 39(3):447-457. IF: 4.004. (Quartile 2; Oncology area)     

Gómez-Gómez E, Jiménez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, León-González AJ, Valero-Rosa J, Fernández-Rueda JL, González-Serrano T, López-Miranda J, Gahete MD, Castaño JP, Requena-Tapia MJ, Luque RM. Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer. J Cell Mol Med 2018, 22(11):5688-5697. FI: 4.658. (Quartile 1; Medicine, Research & Experimental area)

Venegas-Moreno E, Vazquez-Borrego MC, Dios E, Gros-Herguido N, Flores-Martinez A, Rivero-Cortes E, Madrazo-Atutxa A, Japon MA, Luque RM, Castaño JP, Cano DA, Soto-Moreno A. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med 2018, 22(3)1640-1649. IF: 4.658. (Quartile 1; Medicine, Research & Experimental area)    

Jimenez-Lucena R, Rangel-Zuniga OA, Alcala-Diaz JF, Lopez-Moreno J, Roncero-Ramos I, Molina-Abril H, Yubero-Serrano EM, Caballero-Villarraso J, Delgado-Lista J, Castaño JP, Ordovas JM, Perez-Martinez P, Camargo A, Lopez-Miranda J. Circulating miRNAs as Predictive Biomarkers of Type 2 Diabetes Mellitus Development in Coronary HeartDisease Patients from the CORDIOPREV Study. Mol Ther nucleid acids 2018, 12:146-157. IF: 5.919. (Decil 1;   Medicine, research & experimental area)

Roncero-Ramos I, Rangel-Zuniga OA, Lopez-Moreno J, Alcala-Diaz JF, Perez-Martinez P, Jimenez-Lucena R, Castaño JP, Roche HM, Delgado-Lista J, Ordovas JM, Camargo A, Lopez-Miranda J. Mediterranean Diet, Glucose Homeostasis, and Inflammasome Genetic Variants: The CORDIOPREV Study. Mol Nutr Food Res 2018, 62(9):e1700960. IF: 4.653.  (Decil 1; Food Science and Technology area)

Gomez-Delgado F, Delgado-Lista J, Lopez-Moreno J, Rangel-Zuniga OA, Alcala-Diaz JF, Leon-Acuna A, Corina A, Yubero-Serrano E, Torres-Pena JD, Camargo A, Garcia-Rios A, Caballero J, Castaño JP, Ordovas JM, Lopez-Miranda J, Perez-Martinez P. Telomerase RNA Component Genetic Variants Interact With the Mediterranean Diet Modifying the Inflammatory Status and its Relationship With Aging: CORDIOPREV Study. J Gerontol A Biol Sci Med  2018, 73(3):327-332. IF: 4.711. (Quartile 1; Geriatrics & Gerontology area)

Main Publications 2017

Capdevila J, Casanovas O, Salazar R, Castellano D, Segura A, Fuster P, Aller J, Garcia-Carbonero R, Jimenez-Fonseca P, Grande E, Castaño JP. Translational research in neuroendocrine tumors: pitfalls and opportunities. ONCOGENE. 2017. 36(14):1899-1907.
IF: 7,519
Q: 1  D: 1

Hormaechea-Agulla D, Gahete MD, Jimenez-Vacas JM, Gomez-Gomez E, Ibanez-Costa A, L-Lopez F, Rivero-Cortes E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sanchez-Sanchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. MOLECULAR CANCER. 2017. 16(1):146.
IF: 6,204
Q: 1 

Hormaechea-Agulla D, Jimenez-Vacas JM, Gomez-Gomez E, Lopez FL, Carrasco-Valiente J, Valero-Rosa J, Moreno MM, Sanchez-Sanchez R, Ortega-Salas R, Gracia-Navarro F, Culler MD, Ibanez-Costa A, Gahete MD, Requena MJ, Castaño JP, Luque RM. The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB JOURNAL. 2017. 31(11): 4682-4696.
IF: 5,498
Q: 1  D: 1

Luque RM, Lopez-Sanchez LM, Villa-Osaba A, Luque IM, Santos-Romero AL, Yubero-Serrano EM, Cara-Garcia M, Alvarez-Benito M, Lopez-Miranda J, Gahete MD, Castaño JP. Breast cancer is associated to impaired glucose/insulin homeostasis in premenopausal obese/overweight patients. ONCOTARGET. 2017. 8(46):81462-81474.
IF: 5,168
Q: 1 

Sarmento-Cabral A, L-Lopez F, Gahete MD, Castaño JP, Luque RM. Metformin reduces prostate tumor growth, in a diet-dependent manner, by modulating multiple signaling Pathways. MOLECULAR CANCER RESEARCH. 2017. 15(7):862-874.
IF: 4,974
Q: 1 

L-Lopez F, Sarmento-Cabral A, Herrero-Aguayo V, Gahete MD, Castaño JP, Luque RM. Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and IGF1. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2017. 21(9):1893-1904.
IF: 4,499
Q: 1 

Herrera-Martinez AD, Gahete MD, Sanchez-Sanchez R, Salas RO, Serrano-Blanch R, Salvatierra A, Hofland LJ, Luque RM, Galvez-Moreno MA, Castaño JP. The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features. LUNG CANCER. 2017. 109:128-136.
IF: 4,294
Q: 1 

Sarmento-Cabral A, L-Lopez F, Luque RM. Adipokines and their receptors are widely expressed and distinctly regulated by the metabolic environment in the prostate of male mice: Direct role under normal and tumoral conditions. ENDOCRINOLOGY. 2017. 158(10):3540-3552.
IF: 4,283
Q: 1 

Ibanez-Costa A, Lopez-Sanchez LM, Gahete MD, Rivero-Cortes E, Vazquez-Borrego MC, Galvez MA, de la Riva A, Venegas-Moreno E, Jimenez-Reina L, Moreno-Carazo A, Tinahones FJ, Maraver-Selfa S, Japon MA, Garcia-Arnes JA, Soto-Moreno A, Webb SM, Kineman RD, Culler MD, Castaño JP, Luque RM. BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. SCIENTIFIC REPORTS. 2017. 7():42002.
IF: 4,259
Q: 1 

Sarmento-Cabral A, Peinado JR, Halliday LC, Malagón MM, Castaño JP, Kineman RD, Luque RM. Adipokines (Leptin, Adiponectin, Resistin) differentially regulate all hormonal cell types in primary anterior pituitary cell cultures from two primate species. SCIENTIFIC REPORTS. 2017. 7:43537.
IF: 4,259
Q: 1 

Pedraza-Arévalo S, Hormaechea-Agulla D, Gomez-Gomez E, Requena MJ, Selth LA, Gahete MD, Castaño JP, Luque RM. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer. PROSTATE. 2017. 77(15):1499-1511.
IF: 3,82
Q: 1 

Ibanez-Costa A, Luque RM, Castaño JP. Cortistatin: A new link between the growth hormone/prolactin axis, stress, and metabolism. GROWTH HORMONE & IGF RESEARCH. 2017. 33:23-27.
IF: 1,828
Q: 4 

Clinical Research

Ensayo clínico multicéntrico, aleatorizado, controlado, con evaluador ciego, para evaluar la eficacia y la seguridad de un hidrogel que contiene extracto de hoja de olivo como tratamiento de úlceras cutáneas.
PI: Dr. Paloma Moreno Moreno

Members

Team

Francisco Gracia Navarro, Cristóbal José Blanco Acevedo, Sergio Pedraza Arévalo, Ricardo Blázquez Encinas-Rey, Mª Teresa Caro Cuenca, Antonio Carlos Fuentes Fayos, Manuel Jiménez Fuyer, Paloma Moreno Moreno, Marina Esther Sánchez Frías, Javier del Teso Rodríguez, Esther Rivero Cortés